Equity in Cardio-Oncology Care and Research
Published: June 28, 2023
- Cardiovascular disease (CVD) has become a leading cause of non-malignant morbidity and mortality in patients with cancer in the United States, however disparately high mortality risk following a cancer diagnosis is seen among females and those from underrepresented racial and ethnic groups.
- Inequities in cardio-oncology are defined as differences in the optimal allocation of cardio-protective medications, surveillance, and development of adverse outcomes related to cancer therapy-related cardiac disease or outcomes between groups of different race, ethnicity, socioeconomic status, sexual orientation, and gender identity.
- The multidisciplinary scientific statement provides practical strategies for reducing inequity in cardio-oncology and aims to move toward equity.
Supporting Materials
- Commentary: Disparities in Cardio-Oncology by Abdulaziz Hamid; Generika Berman; Luisel Ricks-Santi, PhD; Sherry-Ann Brown MD, PhD
- Top Things to Know: Equity in Cardio-Oncology Care and Research
Recommended Reading
- 2021 Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications
- 2021 Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors
- 2020 Call to Action: Structural Racism as a Fundamental Driver of Health Disparities
- 2020 Assessing and Addressing Cardiovascular Health in LGBTQ Adults
- 2020 Perceptions on Diversity in Cardiology: A Survey of Cardiology Fellowship Training Program Directors
- 2018 Cardiovascular Disease and Breast Cancer: Where These Entities Intersect
- 2017 Cardiovascular Health in African Americans